Bismuth nanoparticles against microbial infections

Papers of special note have been highlighted as: • of interest

References

• 1. Gaynor D, Griffith DM. The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. Dalton. Trans. 41, 13239–13257 (2012).
  Medline CASGoogle Scholar
• 2. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 11(Suppl. 1), 27–33 (1997).
  MedlineGoogle Scholar
• 3. Bierer DW. Bismuth subsalicylate: history, chemistry, and safety. Rev. Infect. Dis. 12, S3–S8 (1990).
  Medline CASGoogle Scholar
• 4. Anderson LG. The treatment of infected suppurating war wounds. Lancet 188, 447 (1916).
  Google Scholar
• 5. Menge H, Gregor M, Brosius B et al. Pharmacology of bismuth. Eur. J. Gastroenterol. Hepatol. 4, S41–S47 (1992).
  Google Scholar
• 6. Crossland G, Bath AJ. Bismuth iodoform paraffin paste: a review. J. Lar. Otol. 125, 891–895 (2011).
  CASGoogle Scholar
• 7. Barillo DJ, Barillo AR, Korn S et al. The antimicrobial spectrum of Xeroform^®. Burns 43, 1189–1194 (2017).
  MedlineGoogle Scholar
• 8. Mohan R. Green bismuth. Nat. Chem. 2, 336 (2010).
  Medline CASGoogle Scholar
• 9. Milenic DE, Baidoo KE, Shih JH et al. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biother. Radiopharm. 28, 441–449 (2013).
  Medline CASGoogle Scholar
• 10. Sun H (Ed.). Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley & Sons, Chichester, UK (2010).
  Google Scholar
• 11. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. Suppl. 112, 212–239 (2017).
  Google Scholar
• 12. Li H, Wang R, Sun HJ. Systems approaches for unveiling the mechanism of action of bismuth drugs. Acc. Chem. Res. 52, 216–227 (2018). • Discusses several broad methodologies for mechanistic research of bismuth drugs, such as system pharmacology and metalloproteomics approaches. Demonstrates that the selective toxicity of bismuth drugs against Helicobacter pylori is associated with glutathione- and multidrug-resistance-associated protein 1.
  MedlineGoogle Scholar
• 13. Wang R, Li H, Ip TK-Y, Sun H. Bismuth drugs as antimicrobial agents. Adv. Inorg. Chem. 75, 183–205 (2020).
  CASGoogle Scholar
• 14. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS. Microbiol. 4, 482–501 (2018).
  Medline CASGoogle Scholar
• 15. Gisbert JP. Helicobacter pylori eradication: a new, single-capsule bismuth-containing quadruple therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 307–309 (2011).
  Medline CASGoogle Scholar
• 16. Vazquez-Munoz R, Arellano-Jimenez MJ, Lopez-Ribot JL. Bismuth nanoparticles obtained by a facile synthesis method exhibit antimicrobial activity against Staphylococcus aureus and Candida albicans. BMC Biomed. Eng. 2, 1–12 (2020).
  MedlineGoogle Scholar
• 17. Domenico P, Baldassarri L, Schoch PE et al. Chemotherapy activities of bismuth thiols against staphylococci and staphylococcal biofilms. Antimicrob. Agents Chemother. 45, 1417–1421 (2001).
  Medline CASGoogle Scholar
• 18. Alipour M, Suntres ZE, Lafrenie RM, Omri AJ. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth–ethanedithiol with tobramycin in liposomes. J. Antimicrob. Chemother. 65, 684–693 (2010).
  Medline CASGoogle Scholar
• 19. Griffith DM, Li H, Werrett MV et al. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem. Soc. Rev. 50, 12037–12069 (2021). • The unique and biological chemistry of bismuth against H. pylori and the development of its new compounds for the treatment of microbial infection and as an antiresistance factor are highlighted.
  Medline CASGoogle Scholar
• 20. Reardon S. Bacterial arms race revs up. Nature 521, 402–403 (2015).
  Medline CASGoogle Scholar
• 21. Mandal SM, Roy A, Ghosh AK et al. Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front. Pharmacol. 5, 105 (2014).
  MedlineGoogle Scholar
• 22. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, S122–S129 (2004).
  Medline CASGoogle Scholar
• 23. Lobanovska M, Pilla G. Focus: drug development. Penicillin's discovery and antibiotic resistance: lessons for the future? J. Biol. Med. 90, 135 (2017).
  CASGoogle Scholar
• 24. Katz ML, Mueller LV, Polyakov M, Weinstock SF. Where have all the antibiotic patents gone? Nat. Biotechnol. 24, 1529–1531 (2006).
  Medline CASGoogle Scholar
• 25. Freire-Moran L, Aronsson B, Manz C et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria – time to react is now. Drug. Resist. Updat. 14, 118–124 (2011).
  MedlineGoogle Scholar
• 26. Hernando-Amado S, Coque TM, Baquero F, Martínez JL. Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat. Microbiol. 4, 1432–1442 (2019).
  Medline CASGoogle Scholar
• 27. Baur D, Gladstone BP, Burkert F et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 990–1001 (2017).
  MedlineGoogle Scholar
• 28. Hooton TM, Levy SB. Antimicrobial resistance: a plan of action for community practice. Am. Fam. Physician 63, 1087 (2001).
  Medline CASGoogle Scholar
• 29. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin. Proc. 86, 156–167 (2011).
  MedlineGoogle Scholar
• 30. White A, Hughes JMJE. Critical importance of a one health approach to antimicrobial resistance. EcoHealth 16, 404–409 (2019).
  MedlineGoogle Scholar
• 31. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol. 1, 134 (2010).
  MedlineGoogle Scholar
• 32. Wang R, Lai T-P, Gao P et al. Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors. Nat. Commun. 9, 1–12 (2018). • Investigates the effects of colloidal bismuth subcitrate (CBS) and similar Bi (III) compounds on metallo-β-lactamases (MBLs) bacteria. CBS restores the efficacy of meropenem against MBL-positive bacteria in in vitro and mice infection models. Importantly, it also retards the development of resistance at greater levels in NDM-1-positive bacteria.
  MedlineGoogle Scholar
• 33. Claudio C-R, Chellam S. Bismuth nanoparticles: antimicrobials of broad-spectrum, low cost and safety. Nanomed. 430–437 (2014).
  Google Scholar
• 34. Azad A, Rostamifar S, Modaresi F et al. Assessment of the antibacterial effects of bismuth nanoparticles against Enterococcus faecalis. Biomed. Res. Int. (2020).
  Google Scholar
• 35. Muhammad W, Haleemb I, Ullahc N et al. Nanoparticle synthesis approaches at a glance. Nanoscale Rep. 2, 1–10 (2019).
  Google Scholar
• 36. Ding K, Cullen DA, Zhang L et al. A general synthesis approach for supported bimetallic nanoparticles via surface inorganometallic chemistry. Science 362, 560–564 (2018).
  Medline CASGoogle Scholar
• 37. Jamkhande PG, Ghule NW, Bamer AH, Kalaskar MG. Metal nanoparticles synthesis: an overview on methods of preparation, advantages and disadvantages, and applications. J. Drug. Deliv. Sci. Technol. 53, 101174 (2019).
  CASGoogle Scholar
• 38. Bi H, He F, Dong Y et al. Bismuth nanoparticles with ‘light’ property served as a multifunctional probe for x-ray computed tomography and fluorescence imaging. Chem. Mater. 30, 3301–3307 (2018).
  CASGoogle Scholar
• 39. Deng J, Xu S, Hu W et al. Tumor targeted, stealthy and degradable bismuth nanoparticles for enhanced x-ray radiation therapy of breast cancer. Biomaterials. 154, 24–33 (2018).
  Medline CASGoogle Scholar
• 40. Hassanien A, Akl AA, Sáaedi A. Synthesis, crystallography, microstructure, crystal defects, and morphology of Bi x Zn 1– x O nanoparticles prepared by sol–gel technique. CrystEngComm 20, 1716–1730 (2018).
  CASGoogle Scholar
• 41. Chen LQ, Xiao SJ, Peng L et al. Aptamer-based silver nanoparticles used for intracellular protein imaging and single nanoparticle spectral analysis. J. Phys. Chem. B. 114, 3655–3659 (2010).
  Medline CASGoogle Scholar
• 42. Chen H, Shin D-W, Nam J-G et al. Selenium nanowires and nanotubes synthesized via a facile template-free solution method. Mater. Res. Bull. 45, 699–704 (2010).
  CASGoogle Scholar
• 43. Chen Z, Shen Y, Xie A et al. L-Cysteine-assisted controlled synthesis of selenium nanospheres and nanorods. Cryst. Growth Des. 9, 1327–1333 (2009).
  CASGoogle Scholar
• 44. Cao X, Xie Y, Zhang S, Li F. Ultra-thin trigonal selenium nanoribbons developed from series-wound beads. Adv. Mater. 16, 649–653 (2004).
  CASGoogle Scholar
• 45. Zheng W, Li Y, Lee LYS. Bismuth and metal-doped bismuth nanoparticles produced by laser ablation for electrochemical glucose sensing. Sens. Actuators B Chem. 357, 131334 (2021).
  Google Scholar
• 46. Kruis FE, Fissan H, Rellinghaus B. Sintering and evaporation characteristics of gas-phase synthesis of size-selected PbS nanoparticles. Mater. Sci. Eng. B. 69, 329–334 (2000).
  Google Scholar
• 47. Torrisi L, Silipigni L, Restuccia N et al. Laser-generated bismuth nanoparticles for applications in imaging and radiotherapy. J. Phys. Chem. Solids. 119, 62–70 (2018).
  CASGoogle Scholar
• 48. Gao L, Li H, Ren W et al. The high-yield growth of Bi₂Se₃ nanostructures via facile physical vapor deposition. Vacuum 140, 58–62 (2017).
  CASGoogle Scholar
• 49. Khandel P, Yadaw RK, Soni DK et al. Biogenesis of metal nanoparticles and their pharmacological applications: present status and application prospects. J. Nanostruct. Chem. 8, 217–254 (2018).
  CASGoogle Scholar
• 50. Ahmad S, Munir S, Zeb N et al. Green nanotechnology: a review on green synthesis of silver nanoparticles – an ecofriendly approach. Int. J. Nanomed. 14, 5087 (2019).
  Medline CASGoogle Scholar
• 51. Mahiuddin M, Ochiai B. Green synthesis of crystalline bismuth nanoparticles using lemon juice. RSC. Adv. 11, 26683–26686 (2021).
  Medline CASGoogle Scholar
• 52. Das PE, Majdalawieh AF, Abu-Yousef IA et al. Use of a hydroalcoholic extract of Moringa oleifera leaves for the green synthesis of bismuth nanoparticles and evaluation of their anti-microbial and antioxidant activities. Materials 13, 876 (2020). • The green synthesis of bismuth nanoparticles using Moringa oleifera leaf extract was successful, and the produced nanoparticles showed positive antioxidant, antibacterial and antifungal activity.
  Medline CASGoogle Scholar
• 53. Shakibaie M, Amiri-Moghadam P, Ghazanfari M et al. Cytotoxic and antioxidant activity of the biogenic bismuth nanoparticles produced by Delftia sp. SFG. Mater. Res. Bull. 104, 155–163 (2018).
  CASGoogle Scholar
• 54. Dalvand LF, Hosseini F, Dehaghi SM, Torbati ES. Inhibitory effect of bismuth oxide nanoparticles produced by bacillus licheniformis on methicillin-resistant Staphylococcus aureus strains (MRSA). Iran. J. Biotechnol. 4, 16 (2018). • Bismuth oxide nanoparticles were produced by Bacillus licheniformis to determine their antimicrobial effects on methicillin-resistant Staphylococcus aureus species in comparison with some antibiotics.
  Google Scholar
• 55. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Future Med. 2, 789–803 (2007).
  CASGoogle Scholar
• 56. Bogner A, Thollet G, Basset D et al. Wet STEM: a new development in environmental SEM for imaging nano-objects included in a liquid phase. Ultramicroscopy 104, 290–301 (2005).
  Medline CASGoogle Scholar
• 57. Joshi M, Bhattacharyya A, Ali SW. Characterization techniques for nanotechnology applications in textiles. Ind. J. Fibre Textile Res. 33, 304–317 (2008).
  CASGoogle Scholar
• 58. Campos EA, Pinto DVBS, de Oliveira JIS. Synthesis, characterization and applications of iron oxide nanoparticles-a short review. J. Aerosp. Technol. 7, 267–276 (2015).
  CASGoogle Scholar
• 59. Tiede K, Boxall AB, Tear SP et al. Detection and characterization of engineered nanoparticles in food and the environment. Food. Addit. Contam. 25, 795–821 (2010).
  Google Scholar
• 60. Kim H-S, Ahn J-Y, Hwang K-Y et al. Atmospherically stable nanoscale zero-valent iron particles formed under controlled air contact: characteristics and reactivity. Environ. Sci. Technol. 44, 1760–1766 (2010).
  Medline CASGoogle Scholar
• 61. Scimeca M, Bischetti S, Lamsira HK et al. Energy dispersive x-ray (EDX) microanalysis: a powerful tool in biomedical research and diagnosis. Eur. J. Histochem. 1, EJH 62 (2018).
  Google Scholar
• 62. Poole RK, Kalnenieks U. Introduction to light absorption: visible and ultraviolet spectra. In: Spectrophotometry and Spectrofluorimetry: A Practical Approach (2nd Edition). Gore MG (Ed.). Oxford University Press, Oxford, UK (2000).
  Google Scholar
• 63. Singh J, Dutta T, Kim K-H et al. ‘Green’ synthesis of metals and their oxide nanoparticles: applications for environmental remediation. J. Nanobiotechnol. 16, 1–24 (2018).
  MedlineGoogle Scholar
• 64. Rosa RGT, de Araujo Duarte C, Schreiner WH et al. Structural, morphological and optical properties of Bi NPs obtained by laser ablation and their selective detection of L-cysteine. Colloids Surf. A Physicochem. Eng. Asp. 457, 368–373 (2014).
  CASGoogle Scholar
• 65. Sharma B, Frontiera RR, Henry A-I et al. SERS: materials, applications, and the future. Mater. Today 15, 16–25 (2012).
  CASGoogle Scholar
• 66. Fernández B, Costa JM, Pereiro R, Sanz-Medel A. Inorganic mass spectrometry as a tool for characterisation at the nanoscale. Anal. Bioanal. Chem. 396, 15–29 (2010).
  Medline CASGoogle Scholar
• 67. Sapsford KE, Tyner KM, Dair BJ et al. Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. Anal. Chem. 83, 4453–4488 (2011).
  Medline CASGoogle Scholar
• 68. Clogston JD, Patri AK. Zeta potential measurement. Methods Mol. Biol. 697, 63–70 (2011).
  Medline CASGoogle Scholar
• 69. Inagaki S, Ghirlando R, Grisshammer R. Biophysical characterization of membrane proteins in nanodiscs. Methods 59, 287–300 (2013).
  Medline CASGoogle Scholar
• 70. Drake AF. Polarisation modulation – the measurement of linear and circular dichroism. J. Phys. E: Sci. Instr. 19, 170 (1986).
  CASGoogle Scholar
• 71. Kaur G, Dogra V, Kumar R et al. DNA interaction, anti-proliferative effect of copper oxide nanocolloids prepared from metallosurfactant based microemulsions acting as precursor, template and reducing agent. Int. J. Pharm. 535, 95–105 (2018).
  Medline CASGoogle Scholar
• 72. Maliha M, Herdman M, Brammananth R et al. Bismuth phosphinate incorporated nanocellulose sheets with antimicrobial and barrier properties for packaging applications. J. Clean. Prod. 246, 119016 (2020).
  CASGoogle Scholar
• 73. Hernandez-Delgadillo R, Velasco-Arias D, Diaz D et al. Zerovalent bismuth nanoparticles inhibit Streptococcus mutans growth and formation of biofilm. Int. J. Nanomed. 8, 1645 (2013).
  MedlineGoogle Scholar
• 74. Cabral-Romero C, Chellam S. Bismuth nanoparticles: antimicrobials of broad-spectrum, low cost and safety. Nanomedicine 429, 429 (2014).
  Google Scholar
• 75. Werrett MV, Herdman ME, Brammananth R et al. Bismuth phosphinates in Bi-nanocellulose composites and their efficacy towards multi-drug resistant bacteria. Chemistry 24, 12938–12949 (2018).
  Medline CASGoogle Scholar
• 76. Hernandez-Delgadillo R, del Angel-Mosqueda C, Solís-Soto JM et al. Antimicrobial and antibiofilm activities of MTA supplemented with bismuth lipophilic nanoparticles. Dent. Mater. J. 36, 503–510 (2017).
  Medline CASGoogle Scholar
• 77. Yang Y, Ouyang R, Xu L et al. Review: bismuth complexes: synthesis and applications in biomedicine. J. Coord. Chem. 68, 379–397 (2015).
  CASGoogle Scholar
• 78. Badireddy A, Chellam S. Antibacterial and antifouling properties of lipophilic bismuth compounds. Adv. Chem. Res. Nova Sci. 21, 1–22 (2014).
  CASGoogle Scholar
• 79. Campos V, Almaguer-Flores A, Velasco-Aria D et al. Bismuth and silver nanoparticles as antimicrobial agent over subgingival bacterial and nosocomial strains. Mater. Sci. Eng. A8, 142–146 (2018). • Determined the antibacterial effects of three colloidal dispersions of bismuth nanoparticles compared with silver nanoparticles against oral and nosocomial bacteria.
  Google Scholar
• 80. Chen R, Cheng G, So MH et al. Bismuth subcarbonate nanoparticles fabricated by water-in-oil microemulsion-assisted hydrothermal process exhibit anti-Helicobacter pylori properties. Mater. Res. Bull. 45, 654–658 (2010).
  CASGoogle Scholar
• 81. Flores-Castañeda M, Vega-Jiménez AL, Almaguer-Flores A et al. Antibacterial effect of bismuth subsalicylate nanoparticles synthesized by laser ablation. J. Nanoparticle Res. 17, 1–13 (2015).
  CASGoogle Scholar
• 82. Vazquez-Munoz R, Arellano-Jimenez MJ, Lopez-Ribot JL. Bismuth nanoparticles obtained by a facile synthesis method exhibit antimicrobial activity against Staphylococcus aureus and Candida albicans. BMC Biomed. Eng. 2, 11 (2020).
  MedlineGoogle Scholar
• 83. Koczkur KM, Mourdikoudis S, Polavarapu L, Skrabalak SE. Polyvinylpyrrolidone (PVP) in nanoparticle synthesis. Dalton. Trans. 44, 17883–17905 (2015).
  Medline CASGoogle Scholar
• 84. Pramila S, Nagaraju G, Mallikarjunaswamy C et al. Green synthesis of BiVO₄ nanoparticles by microwave method using Aegle marmelos juice as a fuel: photocatalytic and antimicrobial study. Anal. Chem. Lett. 10, 298–306 (2020).
  CASGoogle Scholar
• 85. Mahony D, Woods A, Eelman M et al. Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile. Antimicrob. Agents. Chemother. 49, 431–433 (2005).
  Medline CASGoogle Scholar
• 86. Badireddy AR, Marinakos SM, Chellam S, Wiesner MR. Lipophilic nano-bismuth inhibits bacterial growth, attachment, and biofilm formation. Surf. Innov. 1, 181–189 (2013).
  CASGoogle Scholar
• 87. Badireddy AR, Hernandez-Delgadillo R, Sánchez-Nájera RI et al. Synthesis and characterization of lipophilic bismuth dimercaptopropanol nanoparticles and their effects on oral microorganisms growth and biofilm formation. J. Nanoparticle Res. 16, 1–12 (2014). • Analyzed the bactericidal, fungicidal and antibiofilm activities of bismuth dimercaptopropanol nanoparticles against oral microbes.
  CASGoogle Scholar
• 88. Hernández-Delgadillo R, Espinoza-Villarreal EC, Del Angel-Mosqueda C et al. Antimicrobial and antibiofilm activities of a bismuth lipophilic nanoparticles hydrogel against methicillin-resistant Staphylococcus aureus biofilm. www.researchgate.net/profile/Casiano-Del-Angel-Mosqueda/publication/318672501_Antimicrobial_and_Antibiofilm_Activities_of_a_Bismuth_Lipophilic_Nanoparticles_Hydrogel_against_Methicillin-resistant_Staphylococcus_aureus_biofilm/links/5976f7670f7e9b4016bc565c/Antimicrobial-and-Antibiofilm-Activities-of-a-Bismuth-Lipophilic-Nanoparticles-Hydrogel-against-Methicillin-resistant-Staphylococcus-aureus-biofilm.pdf
  Google Scholar
• 89. Rodríguez-Luis OE, Hernández-Delgadillo R, Pineda-Aguilar N et al. Effect of bismuth lipophilic nanoparticles (BisBAL NPs) on Trichomonas vaginalis growth. J. Nanosci. Nanotechnol. 17, 4618–4622 (2017). • Presents the first evidence of antiparasitic activity of lipophilic bismuth nanoparticles being as effective as metronidazole to interfere with Trichomonas vaginalis growth.
  CASGoogle Scholar
• 90. Nazari P, Dowlatabadi-Bazaz R, Mofid M et al. The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori. Appl. Biochem. Biotechnol. 172, 570–579 (2014).
  Medline CASGoogle Scholar
• 91. Shakibaie M, Hajighasemi E, Adeli-Sardou M et al. Antimicrobial and anti-biofilm activities of Bi subnitrate and BiNPs produced by Delftia sp. SFG against clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa, and Proteus mirabilis. IET Nanobiotec. 13, 377–381 (2019).
  MedlineGoogle Scholar
• 92. Ge R, Sun H. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc. Chem. Res. 40, 267–274 (2007).
  Medline CASGoogle Scholar
• 93. Duffin RN, Werrett MV, Andrews PC. Antimony and bismuth as antimicrobial agents. Adv. Inorg. Chem. 75, 207–255 (2020).
  CASGoogle Scholar
• 94. Sox TE, Olson CA. Chemotherapy. Binding and killing of bacteria by bismuth subsalicylate. Antimicrob. Agents Chemother. 33, 2075–2082 (1989).
  Medline CASGoogle Scholar
• 95. Chen Z, Zhou Q, Ge R. Inhibition of fumarase by bismuth (III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori. Biometals 25, 95–102 (2012).
  Medline CASGoogle Scholar
• 96. Beil W, Birkholz C, Wagner S, Sewing K-F. Bismuth subcitrate and omeprazole inhibit Helicobacter pylori F1-ATPase. Pharmacology 50, 333–337 (1995).
  Medline CASGoogle Scholar
• 97. Claudel M, Schwarte JV, Fromm KM. New antimicrobial strategies based on metal complexes. Chemistry 2, 849–899 (2020).
  CASGoogle Scholar